Table 3 Intragroup analysis of patients treated with subjects treated with conventional therapy + dulaglutide at a three and nine month follow-up

SBP (mm/Hg) (mean ± SD)

137.8 ± 12.1

134.9 ± 10.9

129.7 ± 10.7

< 0.0005*

0.012^

DBP (mm/Hg) (mean ± SD)

76.3 ± 12.3

73.2 ± 9.9

71.9 ± 9.2

0.03*

Weight (Kg) (mean ± SD)

75.7 ± 8.5

73.1 ± 7.6

68.9 ± 8.8

0.02 °

< 0.0005*

0.008^

BMI (kg/m²) (mean ± SD)

27.6 ± 3.4

26.9 ± 3.4

25.2 ± 3.6

< 0.0005*

0.01^

HR (bpm) (mean ± SD)

76.6 ± 11.1

75.6 ± 6.0

75.1 ± 5.3

0.58

Total cholesterol (mg/dl/mmol/L) (mean ± SD)

160.9 ± 20.5 /4.2 ± 0.5

160.3 ± 21.2/ 4.3 ± 0.7

152.3 ± 22.4/3.9 ± 0.5

0.04*

HDL cholesterol (mg/dl/mmol/L) (mean ± SD)

37.4 ± 4.3/0.9 ± 0.1

36.4 ± 4.3/ 0.9 ± 0.1

38.3 ± 6.1/ 0.9 ± 0.1

0.79

LDL cholesterol (mg/dl/mmol/L)

(mean ± SD)

102.7 ± 11.6/2.6 ± 0.3

101.8 ± 10.6 /2.6 ± 0.2

96.0 ± 9.1/2.4 ± 0.2

0.001*

0.002^

Triglycerides (mg/dl/mmol/L)

(mean ± SD)

139.2 ± 13.6/1.6 ± 0.2

138.1 ± 13.2/1.5 ± 0.1

137.5 ± 18.9/1.5 ± 0.2

0.1

FPG (mg/dL/mmol/L) (mean ± SD)

147.6 ± 32.6 /8.2 ± 1.2

131.2 ± 21.9/7.2 ± 1.2

119.3 ± 14.3/6.6 ± 1.0

0.002°

< 0.0005*

0.001^

HBa1C (%) (media ± DS)

7.4 ± 0.7

6.5 ± 0.5

6.2 ± 0.3

< 0.0005*°^

GFR CKD-EPI

(mean ± SD)

77.4 ± 11.2

76.7 ± 10.5

76.7 ± 9.8

0.1

Microalbuminuria

(mg/24 h) (mean ± SD)

80.9 ± 20.9

80.1 ± 16.6

80.1 ± 16.6

0.35

RHI (mean ± SD)

1.7 ± 0.4

1.8 ± 0.4

2.0 ± 0.4

< 0.0005*

PWV (m/s) (mean ± SD)

11.2 ± 0.9

10.8 ± 0.8

10.6 ± 0.8

0.02°

< 0.0005*

Aix (%)(mean ± SD)

105.6 ± 6.9

103.1 ± 6.7

101.8 ± 5.3

0.001*